Suppr超能文献

2型糖尿病患者铁蛋白血症伴肝功能检查异常:病例报告与文献综述

Deranged Liver Function Tests Associated With Hyperferritinemia in a Patient With Type 2 Diabetes Mellitus: A Case Study and Literature Review.

作者信息

Elmakki Erwa Eltayib

机构信息

Department of Internal Medicine, Faculty of Medicine, Jazan University, Jazan, SAU.

出版信息

Cureus. 2024 Aug 3;16(8):e66074. doi: 10.7759/cureus.66074. eCollection 2024 Aug.

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a common complication in patients with type 2 diabetes mellitus (T2DM), potentially progressing to more severe conditions such as metabolic dysfunction-associated steatohepatitis (MASH), liver cirrhosis, and hepatocellular carcinoma. This case study presents a 55-year-old man with long-standing T2DM who was found to have deranged liver function tests, elevated serum iron, and hyperferritinemia during a routine follow-up visit. The patient's clinical presentation, laboratory findings, and imaging results led to a diagnosis of MASH, complicated by dysregulated iron metabolism. This case highlights the importance of vigilant monitoring of liver function and iron studies in T2DM patients. Furthermore, it illustrates the challenges in managing the complex interplay between metabolic syndrome, liver dysfunction, and cardiovascular risk.

摘要

代谢功能障碍相关脂肪性肝病(MASLD)是2型糖尿病(T2DM)患者常见的并发症,可能进展为更严重的疾病,如代谢功能障碍相关脂肪性肝炎(MASH)、肝硬化和肝细胞癌。本病例研究介绍了一名55岁患有长期T2DM的男性,在一次常规随访中发现其肝功能检查结果异常、血清铁升高和铁蛋白血症。患者的临床表现、实验室检查结果和影像学结果导致诊断为MASH,并伴有铁代谢失调。该病例强调了对T2DM患者肝功能和铁代谢研究进行密切监测的重要性。此外,它还说明了在管理代谢综合征、肝功能障碍和心血管风险之间复杂相互作用方面所面临的挑战。

相似文献

5
NAFLD (MASLD)/NASH (MASH): Does It Bother to Label at All? A Comprehensive Narrative Review.
Int J Mol Sci. 2024 Aug 2;25(15):8462. doi: 10.3390/ijms25158462.
6
One-step non-invasive diagnosis of metabolic dysfunction-associated steatohepatitis and fibrosis in high-risk population.
United European Gastroenterol J. 2024 Sep;12(7):919-929. doi: 10.1002/ueg2.12589. Epub 2024 Aug 4.
7
The Lasting Effects of COVID-19 on the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
Cureus. 2023 Sep 14;15(9):e45231. doi: 10.7759/cureus.45231. eCollection 2023 Sep.
8
A prospective study on the prevalence of at-risk MASH in patients with type 2 diabetes mellitus in the United States.
Aliment Pharmacol Ther. 2024 Jun;59(12):1571-1578. doi: 10.1111/apt.17997. Epub 2024 Apr 8.

本文引用的文献

1
Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.
N Engl J Med. 2024 Jul 25;391(4):299-310. doi: 10.1056/NEJMoa2401943. Epub 2024 Jun 8.
2
In NASH with liver fibrosis, resmetirom improved NASH resolution and reduced fibrosis at 1 y.
Ann Intern Med. 2024 Jun;177(6):JC63. doi: 10.7326/ANNALS-24-00206-JC. Epub 2024 Jun 4.
4
A prospective study on the prevalence of at-risk MASH in patients with type 2 diabetes mellitus in the United States.
Aliment Pharmacol Ther. 2024 Jun;59(12):1571-1578. doi: 10.1111/apt.17997. Epub 2024 Apr 8.
5
Iron metabolism and ferroptosis in nonalcoholic fatty liver disease: what is our next step?
Am J Physiol Endocrinol Metab. 2024 Jun 1;326(6):E767-E775. doi: 10.1152/ajpendo.00260.2023. Epub 2024 Mar 20.
6
MASLD: a systemic metabolic disorder with cardiovascular and malignant complications.
Gut. 2024 Mar 7;73(4):691-702. doi: 10.1136/gutjnl-2023-330595.
7
Exploring the links between types 2 diabetes and liver-related complications: A comprehensive review.
United European Gastroenterol J. 2024 Mar;12(2):240-251. doi: 10.1002/ueg2.12508. Epub 2023 Dec 16.
8
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review.
J Obes Metab Syndr. 2023 Sep 30;32(3):197-213. doi: 10.7570/jomes23052. Epub 2023 Sep 13.
9
Statins on nonalcoholic fatty liver disease: A systematic review and meta-analysis of 14 RCTs.
Medicine (Baltimore). 2023 Jun 30;102(26):e33981. doi: 10.1097/MD.0000000000033981.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验